Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 322 clinical trials
featured
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer  

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival …

breast cancer
letrozole
measurable disease
erbb2
her2/neu-negative breast cancer
  • 23 views
  • 09 Sep, 2021
  • 4 locations
featured
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (Alliance A151216)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (Alliance A151216)

lung carcinoma
cancer
lung cancer
  • 72 views
  • 03 Dec, 2020
  • 1 location
featured
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

  • 430 views
  • 23 Nov, 2020
  • 1 location
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.

  • 0 views
  • 24 Jan, 2021
  • 21 locations
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

disease (SD) after induction treatment with a selected therapy (Molecular Targeted Therapy (MTT) or with SD, partial response (PR) or complete reponse (CR) with Immunotherapy (IT)). For MTT, the

  • 0 views
  • 20 Sep, 2021
  • 13 locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted

  • 2 views
  • 19 Sep, 2021
  • 78 locations
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

At present targeted therapy with the PARP inhibitor olaparib has become standard of care in advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the loss of

  • 0 views
  • 25 Jan, 2021
  • 1 location
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

therapy, herceptin targeted therapy or hormone therapy according to the NCCN (2011) guideline. The follow-up will be ten years after surgeries. The primary aim is to examine whether the docetaxel and

  • 0 views
  • 21 Jan, 2021
  • 14 locations
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients 16 Years With Centronuclear Myopathies

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of a new medicine called DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1. The trial will …

  • 2 views
  • 20 Sep, 2021
  • 11 locations
Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET

The purpose of this study is to investigate whether oral Gushen Antai pills supplementation for luteal phase support will improve ongoing pregnancy rate in women with normal ovarian reserve in fresh embryo transfer cycles.

  • 0 views
  • 10 Aug, 2021
  • 1 location